Molecular Targeting Technologies, Inc. (MTTI) announces that response of colorectal cancer to treatment can be detected with their innovative diagnostic agent (Tc-99m duramycin-TumorVue) as early as one day after a single administration of drug. Results from this preclinical study were published online.

“Although imaging agents such as 18F-FDG show great promise as biomarkers for early response to targeted cancer therapy, conflicting results are reported after immunotherapy. If our preclinical findings can be confirmed in patients, TumorVue has the potential to fill this gap since it does not seem to be hampered by the presence or absence of an inflammatory response,” said Professor Sigrid Stroobants of the Antwerp University Hospital (UZA).

“Detection of early treatment response will allow for improved management of cancer patients in the clinic. This study demonstrated that TumorVue™ enables readout of tumor response to targeted therapy as early as one day after start of treatment,” said Dr. Leonie Wyffels at the University of Antwerp’s Molecular Imaging Center Antwerp (UAntwerp-MICA). “The superiority of TumorVue™ over 18F-FDG for early detection of treatment response in colorectal tumors is exciting.”

Chris Pak, president and CEO of MTTI said, “We are encouraged by the results of TumorVue for detection of treatment response to targeted therapy as early as one day. Our goal is to translate these findings into patients to differentiate responders from non-responders. This innovative agent will be a powerful tool for personalized medicine where cancer patients will be spared the toxicity of ineffective therapy.”

For more information: www.uantwerp.be

Related Content

News | Nuclear Imaging

November 22, 2021 — IBA, a leader in particle accelerator technology, and NorthStar Medical Radioisotopes LLC, a global ...

Time November 22, 2021
arrow
Videos | Radiopharmaceuticals and Tracers

Ana Kiess, M.D., Ph.D., assistant professor of radiation oncology and molecular radiation sciences, Johns Hopkins ...

Time November 17, 2021
arrow
News | Digital Pathology

November 15, 2021 — Saltus Biotech, a leader in 8k image technology, introduces a new high-end computer workstation and ...

Time November 15, 2021
arrow
News | Molecular Imaging

October 29, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time October 29, 2021
arrow
News | Radiation Therapy

October 19, 2021 — RAD Technology Medical Systems (RAD) announced that it will be exhibiting at the 2021 American ...

Time October 19, 2021
arrow
News | PET Imaging

October 19, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time October 19, 2021
arrow
News | PET Imaging

October 18, 2021 — PSMA (prostate-specific membrane antigen) PET/CT is more accurate than conventional CT in the ...

Time October 18, 2021
arrow
News | Radiation Therapy

October 7, 2021 — NANOBIOTIX, a late-stage clinical biotechnology company pioneering physics-based approaches to expand ...

Time October 07, 2021
arrow
Feature | Cardiac Imaging

October 6, 2021 – A new study published in Radiology: Cardiothoracic Imaging on cardiac imaging trends over a decade ...

Time October 06, 2021
arrow
News | Magnetic Resonance Imaging (MRI)

September 20, 2021 — Gadolinium-based contrast agents, the gold standard in magnetic resonance imaging (MRI) to ...

Time September 20, 2021
arrow
Subscribe Now